Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes

ORAMED PHARMACEUTICALS INC.

Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.
Trial to assess safety/efficacy in approximately 300 type 2 diabetes patients under US IND.
Total consideration up to ~$11.5 million, paid monthly based on hours performed over engagement.
Sponsor can terminate with or without cause on 30 days' notice; standard cure period for breach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.